We observed markedly increased PRDX1 levels in both BLCA tissues and cultured cell lines, where elevated expression linked to worse patient outcomes and more aggressive clinical characteristics, including higher tumor grades and stages. The gene discussed is PRDX1; the disease is bladder transitional cell carcinoma.